Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 407

Sort by

Sort Order Select

Journal Articles

Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT

Blood (2019) 134 (Supplement_1): 698.

https://doi.org/10.1182/blood-2019-125802

Published: 2019

Journal Articles

Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT

Arnon Nagler, MD MSc, Myriam Labopin, MD, Emanuele Angelucci, MD, Yener Koc, MD, Mutlu Arat, MD, Pietro Pioltelli, MD, Simona Sica, MD, Zafer Gülbas, MD, Johanna Tischer, MD, Paolo Bernasconi, MD, Jiri Pavlu, MDMRCP,FRCPath, Gerard Socie, MD PhD, Didier Blaise, MD PhD, Luigi Rigacci, MD, Massimo Martino, MD, José Luis Díez-Martín, MD PhD, Zinaida Peric, MD PhD, Sebastian Giebel, MD PhD, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 589.

https://doi.org/10.1182/blood-2019-121644

Published: 2019

Journal Articles

Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls

Stefan O. Ciurea, MD, Roland Bassett, Doris Soebbing, Gabriela Rondon, MD, Kai Cao, MS, MD, Amanda L. Olson, MD, Qaiser Bashir, MBBS, Elizabeth J. Shpall, MD, Steven Devine, Marcelo C. Pasquini, MD, Andrew St. Martin, MS, Dean Anthony Lee, MD PhD, Richard E Champlin

Blood (2019) 134 (Supplement_1): 700.

https://doi.org/10.1182/blood-2019-123936

Published: 2019

Journal Articles

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study

Bhagirathbhai Dholaria, MBBS, Myriam Labopin, MD, Emanuele Angelucci, MD, Johanna Tischer, MD, Mutlu Arat, MD, Fabio Ciceri, MD, Zafer Gülbas, MD, Hakan Ozdogu, MD, Simona Sica, MD, Jose L. Diez-Martin, MD PhD, Yener Koc, MD, Jane Apperley, MB, ChB, MD, Gerard Socie, MD PhD, Sebastian Giebel, MD PhD, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 320.

https://doi.org/10.1182/blood-2019-122258

Published: 2019

Journal Articles

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Anthony Hunter, MD, Chetasi Talati, MD, David A Sallman, MD, Hannah Asghari, MD BS, Jinming Song, MD PhD, Mohammad Hussaini, MD, Nelli Bejanyan, MD, Hany Elmariah, MD MS, Andrew T Kuykendall, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Asmita Mishra, MD

Blood (2019) 134 (Supplement_1): 149.

https://doi.org/10.1182/blood-2019-131530

Published: 2019

Journal Articles

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

Glen A Kennedy, MBBS FRACP FRCPA, Siok-Keen Tey, MBBS,PhDFRACP,FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Ashish Misra, MBBS, FRACP, Elango Subramoniapillai, MBBS, FRACP, James Morton, MBBS, FRACP, FRCPA, Simon Durrant, FRCP,FRCPath,MBBS, Andrea S Hendon, MBBS, PhD FRACP, FRCPA, John Moore, MDFRACP,FRCPA, David Ritchie, MD PhD, David Gottlieb, MBBS, MD FRACP, FRCPA, Julian Cooney, FRACP,FRCPA,MBBS,, Luke Buizen, BSc (Hons), MSc, Sanjoy K Paul, PhD, Geoff R. Hill, MD

Blood (2019) 134 (Supplement_1): 368.

https://doi.org/10.1182/blood-2019-126285

Published: 2019

Journal Articles

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study

Bhagirathbhai Dholaria, MBBS, Myriam Labopin, MD, Emanuele Angelucci, MD, Fabio Ciceri, MD, José Luis Díez-Martín, MD PhD, Benedetto Bruno, MD, Simona Sica, MD, Yener Koc, MD, Zafer Gulbas, MD, Christoph Schmid, MD, Didier Blaise, MD PhD, Angelo Michele Carella, Giuseppe Visani, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 4584.

https://doi.org/10.1182/blood-2019-122279

Published: 2019

Journal Articles

Unmanipulated Haploidentical Transplant Followed By Post-Transplant Cyclophosphamide and Selective Ex Vivo T-Cell Depleted Haploidentical Transplant Results in Comparable Outcome As Unrelated Cord Blood Transplant for Adults with Haematological Malignancies- a Multicenter Study in Singapore

Cheryl XQ Lim, MBBS,MRCP, Yeh Ching Linn, MBBS, MRCP, Yin Jie Koh, Michelle Poon, MBBS, MRCP, FRCPATH, Aloysius YL Ho, MBBS,FRCP,FRCPath, William YK Hwang, MBBS, FRCP, Lip Kun Tan, MBBS, FRCP, FRCPath, Liang Piu Koh, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 4588.

https://doi.org/10.1182/blood-2019-125261

Published: 2019

Journal Articles

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Maria Queralt Salas, MD, Shiyi Chen, Wilson Lam, MD, David Loach, MD, Fotios V. Michelis, MD PhD, Zeyad Al-Shaibani, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Rajat Kumar, MD, Jonas Mattsson, MD, Arjun Law, MDDM

Blood (2019) 134 (Supplement_1): 4590.

https://doi.org/10.1182/blood-2019-126236

Published: 2019

Journal Articles

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Margaux Damge, Sabine Furst, MD, Bénédicte Devictor, Samia Harbi, MD, Joseph Ciccolini, Angela Granata, MD, Thomas Pagliardini, MD, Boris Calmels, Pharm.D., Claude Lemarie, Pharm.D., Luca Castagna, MD, Valerio Maisano, MD, Faezeh Legrand, MD, Anne-Marie Stoppa, MD, Reda Bouabdallah, Evelyne D'Incan, Norbert Vey, MD PhD, Christian Chabannon, MD PhD, Didier Blaise, MD PhD, Raynier Devillier, MD PhD

Blood (2019) 134 (Supplement_1): 4503.

https://doi.org/10.1182/blood-2019-125994

Published: 2019

Journal Articles

Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

Guldane Cengiz Seval, Nergis Ozturk, Sinem Civriz Bozdag, MD, Meltem Kurt Yuksel, MD, Pervin Topcuoglu, MD, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Gunhan Gurman, MD, Osman Ilhan, Hamdi Akan, MD, Meral Beksac, MD, Selami Kocak Toprak, MD

Blood (2019) 134 (Supplement_1): 4504.

https://doi.org/10.1182/blood-2019-127651

Published: 2019

Journal Articles

Elimination of Acute GvHD with Three Doses of Abatacept Prophylaxis Combined with Post-Transplant Cyclophosphamide after Myeloablative Treosulfan-Based Conditioning in the HLA Identical Sibling and Unrelated (10-12/12) Peripheral Blood Stem Cell Donor Setting: Improved Safety and Efficacy Compared to Alemtuzumab Prophylaxis

Amit Patel, MBBS,PhDFRCPath,MRCP, Jun Yong, MBChB, MRCP(UK)

Blood (2019) 134 (Supplement_1): 4540.

https://doi.org/10.1182/blood-2019-130184

Published: 2019

Journal Articles

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Yin Jie Koh, Michelle Poon, MBBS, MRCP, FRCPATH, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, FRCP, Elson Neo, Aloysius YL Ho, MBBS,FRCP,FRCPath, Lip Kun Tan, MBBS, FRCP, FRCPath, Liang Piu Koh, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 4509.

https://doi.org/10.1182/blood-2019-125246

Published: 2019

Journal Articles

Comparison of Allogeneic Transplant Outcomes Using Conditioning with Different Dose of Busulfan for Children with Acute Myeloid Leukemia

Olesia V Paina, PhD, Zhemal Zarifovna Rakhmanova, Dr., Polina Valerievna Kozhokar, Dr., Anastasia S Frolova, Dr, Kirill Alexandrovich Ekushov, Dr., Luibov Tsvetkova, Tatiana A Bykova, MD PhD, Inna V Markova, Dr., Sergey N. Bondarenko, PhDMD, Ildar M Barkhatov, MD PhD, Aleksandr Alyanski, Elena Babenko, Ivan S Moiseev, MD PhD, Marina O Popova, MD PhD, Elena Vladimirovna Semenova, MD PhD, Ludmila S Zubarovskaya, MD PhD professor, Axel Zander, Boris Afanasyev

Blood (2019) 134 (Supplement_1): 4510.

https://doi.org/10.1182/blood-2019-128155

Published: 2019

Journal Articles

Low Lymphocyte Count at Day 30 after Single Cord Blood Transplantation Had Negative Impact on Survival, Because of Higher NRM Rate

Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Atsushi Wake, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2019) 134 (Supplement_1): 4482.

https://doi.org/10.1182/blood-2019-130662

Published: 2019

Journal Articles

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

Nelli Bejanyan, MD, Mei-Jie Zhang, PhD, Khalid Bo-Subait, Hai-Lin Wang, MPH, Erica D. Warlick, MD, Claudio G Brunstein, MD PhD, Brenda M Sandmaier, MD, Mark Litzow, MD, Partow Kebriaei, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD

Blood (2019) 134 (Supplement_1): 4603.

https://doi.org/10.1182/blood-2019-123513

Published: 2019

Journal Articles

Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants

Cristina F Contreras, BS, Janel R Long-Boyle, PharmD, PhD, Kristin A. Shimano, MD, Jasmeen Dara, MD, James N Huang, MD, Sandhya Kharbanda, MD, Alexis Melton, MD PhD, Christine Higham, MD, Morton J Cowan, MD, Christopher C. Dvorak, MD

Blood (2019) 134 (Supplement_1): 4481.

https://doi.org/10.1182/blood-2019-127218

Published: 2019

Journal Articles

Factors That Dictate Mental Coping Strategies Used By Patients with Acute Myeloid Leukemia

Oren Pasvolsky, MD, Pnina Dorfman Etrog, Ofir Wolach, MD, Karyn Geiger, Orit Horn, Amiad Abrahams, Pia Raanani, MD, Uri Rozovski, MD

Blood (2019) 134 (Supplement_1): 5899.

https://doi.org/10.1182/blood-2019-130908

Published: 2019

Journal Articles

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Barry S. Skikne, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Tara L. Lin, MD, Leyla Shune, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Brian McClune, DO, Abdulraheem Yacoub, MD, Clint Divine, Haitham Abdelhakim, MD, Siddhartha Ganguly, MD, Jennifer Hanses, Carol E Webb, BA, Joseph P. McGuirk, DO

Blood (2019) 134 (Supplement_1): 5743.

https://doi.org/10.1182/blood-2019-130828

Published: 2019

Journal Articles

NK CD56 bright CD16 neg reconstitution over Time (NK56-index) Significantly Impacts Long Term Outcome in Allogeneic Hematopoietic Stem Cell Transplantation

Dante Escorcio-Tavares, Vinicius Campos de Molla, MD, Elisa Y Kimura, Vergilio Colturato, MD, Maura V Ikoma, MD PhD, Victor Gottardello Zecchin, MD, Adriana Seber, MD, Nelson Hamerschlak, MD PhD, Vanderson Rocha, MD PhD, Yana Novis, MD, Mihoko Yamamoto, MD PhD, Marcio Nucci, MD PhD, Celso Arrais-Rodrigues, MD PhD, Matheus Vescovi Gonçalves, MD PhD

Blood (2019) 134 (Supplement_1): 3295.

https://doi.org/10.1182/blood-2019-128263

Published: 2019

NARROW

Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT

Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT

Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Myelogenous Leukemia: ALWP of the EBMT Study

Unmanipulated Haploidentical Transplant Followed By Post-Transplant Cyclophosphamide and Selective Ex Vivo T-Cell Depleted Haploidentical Transplant Results in Comparable Outcome As Unrelated Cord Blood Transplant for Adults with Haematological Malignancies- a Multicenter Study in Singapore

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Comparison of Allogeneic Transplant Outcomes Using Conditioning with Different Dose of Busulfan for Children with Acute Myeloid Leukemia

Low Lymphocyte Count at Day 30 after Single Cord Blood Transplantation Had Negative Impact on Survival, Because of Higher NRM Rate

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants

Factors That Dictate Mental Coping Strategies Used By Patients with Acute Myeloid Leukemia

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

NK CD56 bright CD16 neg reconstitution over Time (NK56-index) Significantly Impacts Long Term Outcome in Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only